All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-18T10:06:13.000Z

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

By Amalia Zachariadis, Claire Baker
Featured
John Mascarenhas
Jun 18, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, about the MANIFEST study. We asked: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?

A number of preclinical studies have shown that the two agents work best in combination in murine models of MPN. Furthermore, results from the MANIFEST clinical trial suggest that CPI-0610 + ruxolitinib demonstrates superior clinical activity over the respective monotherapies.

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

More about...
EHA 2020Myeloproliferative neoplasmsPelabresibPrimary myelofibrosisRuxolitinib

Related articles

Add bookmark

MANIFEST phase II study of ruxolitinib and CPI-0610 in patients with myelofibrosis: An update from Arms 2 and 3

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the results of the MANIFEST phase II trial were...

Jan 11, 2021
Add bookmark

MANIFEST phase II study of ruxolitinib and CPI-0610 in patients with myelofibrosis: An update from Arms 2 and 3

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the...

Jan 11, 2021
Add bookmark

MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?

The MPN Hub were pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, during the 61st American Society of...

Jan 20, 2020
Add bookmark

MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?

The MPN Hub were pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New...

Jan 20, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox